-
公开(公告)号:US20170107175A1
公开(公告)日:2017-04-20
申请号:US15398236
申请日:2017-01-04
申请人: Intrexon Corporation
发明人: Robert E. HORMANN , Inna Shulman , Eva Rodel , Rolf Hilfiker , Susan M. De Paul
IPC分类号: C07C243/38 , A61K47/12 , C07C241/02 , A61K47/24 , A61K47/22 , A01N37/40 , A61K31/166 , A61K47/10
CPC分类号: C07C243/38 , A01N37/28 , A01N37/40 , A61K31/166 , A61K47/10 , A61K47/12 , A61K47/22 , A61K47/24 , C07B2200/07 , C07B2200/13 , C07C241/02 , C12N2710/10341 , C12N2830/002 , Y02A50/401 , Y02A50/409 , Y02A50/411 , Y02A50/423 , Y02A50/475 , Y10T428/2982
摘要: The present disclosure provides crystalline polymorphic and amorphous forms of (R)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(2-ethyl-3-methoxy-benzoyl)-hydrazide (Compound 1) or (S)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(2-ethyl-3-methoxy-benzoyl)-hydrazide (Compound 2). The present disclosure further provides compositions comprising crystalline polymorphic and amorphous forms of Compound 1 or Compound 2 and an excipient, methods of making crystalline polymorphic or amorphous forms of Compound 1 or Compound 2, and methods of using crystalline polymorphic or amorphous forms of Compound 1 or Compound 2 to regulate gene expression in a cell or in a subject.
-
公开(公告)号:US20150045441A1
公开(公告)日:2015-02-12
申请号:US14519408
申请日:2014-10-21
申请人: Intrexon Corporation
发明人: Robert E. HORMANN , Inna Shulman , Eva Rödel , Rolf Hilfiker , Susan M. De Paul
IPC分类号: C07C243/38 , A61K31/166
CPC分类号: C07C243/38 , A01N37/28 , A01N37/40 , A61K31/166 , A61K47/10 , A61K47/12 , A61K47/22 , A61K47/24 , C07B2200/07 , C07B2200/13 , C07C241/02 , C12N2710/10341 , C12N2830/002 , Y02A50/401 , Y02A50/409 , Y02A50/411 , Y02A50/423 , Y02A50/475 , Y10T428/2982
摘要: The present disclosure provides crystalline polymorphic and amorphous forms of (R)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(2-ethyl-3-methoxy-benzoyl)-hydrazide (Compound 1) or (S)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(2-ethyl-3-methoxy-benzoyl)-hydrazide (Compound 2). The present disclosure further provides compositions comprising crystalline polymorphic and amorphous forms of Compound 1 or Compound 2 and an excipient, methods of making crystalline polymorphic or amorphous forms of Compound 1 or Compound 2, and methods of using crystalline polymorphic or amorphous forms of Compound 1 or Compound 2 to regulate gene expression in a cell or in a subject.
摘要翻译: 本公开提供(R)-3,5-二甲基 - 苯甲酸N-(1-叔丁基 - 丁基)-N' - (2-乙基-3-甲氧基 - 苯甲酰基) - 酰肼的结晶多晶型和无定形形式 (化合物1)或(S)-3,5-二甲基 - 苯甲酸N-(1-叔丁基 - 丁基)-N' - (2-乙基-3-甲氧基 - 苯甲酰基) - 酰肼(化合物2)。 本公开进一步提供了包含化合物1或化合物2的结晶多晶型和无定形形式的组合物和赋形剂,制备化合物1或化合物2的结晶多晶型或无定形形式的方法,以及使用化合物1的结晶多晶型或无定形形式的方法或 化合物2以调节细胞或受试者中的基因表达。
-
公开(公告)号:US20140057349A1
公开(公告)日:2014-02-27
申请号:US13947631
申请日:2013-07-22
申请人: Intrexon Corporation
IPC分类号: C12N15/85
CPC分类号: C12N15/85 , A61K31/575 , C07C49/727 , C07C49/753 , C07J9/00 , C07K14/70567 , C07K2319/715 , C12N2830/002
摘要: The present invention relates to steroidal ligands for use in nuclear receptor-based inducible gene expression systems. The invention further relates to methods of modulating the expression of genes of interest with a system containing one or more nuclear receptor complexes and one or more steroidal ligands. Further aspects include ligand compositions including therapeutic compositions.
摘要翻译: 本发明涉及用于基于核受体的诱导型基因表达系统的甾体配体。 本发明还涉及用含有一种或多种核受体复合物和一种或多种甾体配体的系统调节感兴趣的基因表达的方法。 其它方面包括包括治疗组合物的配体组合物。
-
-